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ABSTRACT  42 
Objective: NNT (nicotinamide nucleotide transhydrogenase), one of several genes recently discovered 43 
in familial glucocorticoid deficiencies (FGD), is involved in reactive oxygen species detoxification, 44 
suggesting that extra-adrenal manifestations may occur, due to the sensitivity to oxidative stress of 45 
other organs rich in mitochondria. Here, we sought to identify NNT mutations in a large cohort of 46 
patients with primary congenital adrenal insufficiency without molecular etiology and evaluate the 47 
degree of adrenal insufficiency and onset of extra-adrenal damages.  48 
Methods: Sanger or massive parallel sequencing of NNT and patient monitoring. 49 
Results: Homozygous or compound heterozygous NNT mutations occurred frequently (26%, 13 50 
unrelated families, 18 patients) in our cohort. Seven new mutations were identified: p.Met337Val, 51 
p.Ala863Glu, c.3G>A (p.Met1?), p.Arg129*, p.Arg379*, p.Val665Profs*29, and p.Ala704Serfs*19. 52 
The most frequent mutation, p.Arg129*, was found recurrently in patients from Algeria. Most patients 53 
were diagnosed belatedly (8-18 months) after presenting severe hypoglycemia; others experiencing 54 
stress conditions were diagnosed earlier. Five patients also had mineralocorticoid deficiency at onset. 55 
One patient had congenital hypothyroidism and two cryptorchidism. In follow-up, we noticed 56 
gonadotropic and genitalia impairments (precocious puberty, testicular inclusions, interstitial Leydig 57 
cell adenoma, azoospermia), hypothyroidism and one hypertrophic cardiomyopathy. Intrafamilial 58 
phenotype heterogeneity was observed. 59 
Conclusions: NNT should be sequenced, not only in FGD, but also in all primary adrenal 60 
insufficiencies for which the most frequent etiologies have been ruled out. As NNT is involved in 61 
oxidative stress, careful follow-up is needed to evaluate mineralocorticoid biosynthesis extent, and 62 
gonadal, heart and thyroid function. 63 
64 
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INTRODUCTION 65 
Primary adrenal insufficiency (PAI) is a life threatening disorder. Three types can occur: isolated 66 
mineralocorticoid deficiency, isolated glucocorticoid deficiency, or combined mineralocorticoid and 67 
glucocorticoid deficiency (global adrenal insufficiency). Glucocorticoid deficiencies, also called 68 
ACTH resistance syndromes, are autosomal recessive disorders. They include familial glucocorticoid 69 
deficiency (FGD) (OMIM#202200) and triple A syndrome (AAAS) (OMIM#231550), also known as 70 
Allgrove syndrome 1, 2. Patients present episodes of hypoglycemia in the neonatal period or early 71 
childhood with low or unquantifiable cortisol, elevated ACTH levels and normal aldosterone and 72 
plasma renin measurements. Until 2012, only a half of FGD cases could be explained by homozygous 73 
or compound heterozygous mutations in genes involved in the steroidogenic pathway: MC2R (25%), 74 
MRAP (20%), STAR (5%) and more rarely CYP11A1 3-7. Over the last three years, thanks to whole 75 
exome sequencing, three more causative genes have been discovered: MCM4 (mini chromosome 76 
maintenance deficient 4 homologue), NNT (Nicotinamide Nucleotide Transhydrogenase) and TXNRD2 77 
(Thioredoxin reductase 2) 8-10. 78 
As these genes encode proteins that work together for reactive oxygen species (ROS) detoxification or 79 
DNA replication, the spectrum of pathogenic mechanisms causing PAI is not limited to genes 80 
involved in adrenal development and steroidogenesis.  81 
The incidence of NNT gene mutations in Clark et al’s FGD cohort was around 10% (15 families) and 82 
no predominant mutation was reported (21 private mutations)9. Twelve more families have been 83 
reported (12 additional mutations), some with mineralocorticoid defects 11-16. 84 
NNT encodes an integral protein of the inner mitochondrial membrane that acts as a proton pumping 85 
transhydrogenase 17. In prokaryotic cells, the enzyme is composed of two or three different subunits, 86 
whereas in eukaryotic cells, it is usually composed of a single subunit. The active form of the enzyme 87 
is always a homodimer of approximately 220 kDa. All NNTs show a similar structure with three major 88 
domains. Domain I contains the hydrophilic NAD(H) binding site and domain III, the hydrophilic 89 
NADP(H) binding sites. Domain II constitutes the hydrophobic transmembrane part of the enzyme 90 
that connects domains I and III and forms the proton channel 18. NNT supplies the high concentrations 91 
of NADPH needed for glutathione and thioredoxin antioxidant systems involving enzymes such as 92 
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GPX1 (glutathione peroxidase 1), TXNRD2 and PRDX3 (peroxiredoxin 3). NADPH is a cofactor of 93 
P450 enzymes, notably in steroidogenesis 19-22 (Figure 1).  94 
Meimaridou et al showed reduced, basal and ACTH-stimulated corticosterone, revealing impaired 95 
steroidogenesis in C57BL/6J mice with a spontaneous NNT mutation (an in-frame 5 exon deletion). 96 
Furthermore, they showed increased ROS levels in an NNT knock-down human adrenocortical cell 97 
line 9. Oxidative stress impedes steroidogenesis, which in turn induces more oxidative stress resulting 98 
from electron leaks throughout the steroidogenic pathway. Why it affects adrenal hormone production 99 
preferentially remains unknown. All tissues rich in mitochondria may be affected, resulting in a wide 100 
spectrum of diseases. Phenotypically, C57BL/6J mice do not have adrenal defects but show glucose 101 
intolerance and impaired insulin secretion 23. At present, in humans, NNT mutations are known to be 102 
associated with adrenal insufficiency. Additionally, relationships between decreased NNT activity, 103 
modified mitochondrial redox regulation and cardiac failure have been recently reported 24-26.  104 
The aim of our study was to screen for NNT mutations in fifty families with PAI with no identified 105 
molecular etiologies and to perform a careful follow-up so as to identify any extra-adrenal defects. We 106 
found thirteen families (eighteen patients) with NNT mutations: thirteen patients were diagnosed with 107 
FGD and five with global adrenal insufficiency at onset. A range of functions, i.e., 108 
adrenal/mineralocorticoid, puberty, fertility, heart, pancreatic, thyroid and growth, were subjected to 109 
long-term monitoring. 110 
111 
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PATIENTS AND METHODS 112 
 Patients 113 
The NNT gene was analyzed in fifty patients with primary adrenal insufficiency with no molecular 114 
diagnosis. Informed consent was provided by all enrolled patients and the study was conducted in 115 
accordance with the principles of the Declaration of Helsinki. Very long-chain fatty acids in boys and 116 
17-hydroxyprogesterone in all patients were either within normal limits or low, excluding 117 
adrenoleukodystrophy and 21-hydroxylase deficiency, and adrenal autoantibodies were negative, 118 
excluding an autoimmune disorder. Mutations in STAR, CYP11A1, MC2R and MRAP were excluded 119 
by Sanger sequencing, as were those in NR0B1 for boys.  120 
 Molecular genetic analysis of the NNT gene 121 
Genomic DNA was extracted from EDTA-preserved whole blood using the Nucleon BACC3 kit (GE 122 
healthcare, Chalfont Saint Giles, Buckinghamshire, UK). Sanger sequencing was done for 47 patients 123 
and massive parallel sequencing (MPS) for three (patients 11, 12 and 13 in Table 1). 124 
Sanger sequencing 125 
Selective amplification of the 21 coding exons of the NNT gene was performed in twenty fragments by 126 
PCR using specific primers (available on request). Conventional dideoxy sequencing of exons and 127 
exon-intron boundaries was done using Big-Dye Terminators. Sequencing products were loaded on an 128 
ABI-3730XL and analyzed using SeqScape software v2.5 (Life Technologies, CA, USA). Sequence 129 
variants were designated according to the Human Genome Society recommendations 130 
(www.hgvs.org/rec.html) using the NCBI reference sequences NC_000005.9, NM_012343.3 and 131 
NP_036475 built on the GRCh37/hg19.  132 
Massive parallel sequencing (MPS) or next generation sequencing (NGS) 133 
DNAs were tested using an amplicon-based library preparation. A custom panel targeting 57 genes, 134 
involved in adrenal insufficiency and disorders of sex development, including NNT, was designed 135 
using Ion AmpliSeq designer software (Life Technologies) (coding regions ± 50bp) (article underway, 136 
list available on request). The library preparation was done according to the manufacturer’s 137 
instructions with the Ion AmpliSeq Library Kit v2.0 (Life Technologies). Enrichment and 138 
quantification of target DNA were validated on the Caliper LabChip-GX using the high sensitivity 139 
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assay kit (Caliper LifeSciences Waltham, MA, USA). The patients were barcoded and pooled by 140 
groups of eight to get a sufficient depth of coverage (>100X) at sequencing. For the sequencing step, 141 
enriched template-positive Ion PGM spheres were prepared by emulsion PCR with the Ion OneTouch 142 
2 System (Life Technologies). The resulting live Ion Sphere Particles (ISPs) were loaded on an Ion 143 
316 Chip. Sequencing was done on the Ion Torrent Personal Genome Machine (PGM) with the PGM 144 
Sequencing 200 Kit. The bioinformatics pipeline used was the Torrent Suite software implemented 145 
with the sequencer and with the default parameters. NNT mutations were validated by Sanger 146 
sequencing. 147 
Array comparative genomic hybridization (aCGH) and long range PCR 148 
To confirm a deletion, aCGH or chromosomal microarray (CMA) was performed according to the 149 
manufacturer’s instructions, using the Agilent SurePrint G3 Human CGH Microarray 4x180K 150 
AMADID 022060 (Agilent Technologies, Inc, Santa Clara, CA). This was followed by long-range 151 
PCR using the Qiagen LongRange PCR kit (Qiagen, Hilden, Germany) according to the supplier’s 152 
recommendations. Conventional dideoxy sequencing of the PCR product was done as described in the 153 
paragraph “Sanger sequencing” (primers available on request).  154 
 Pathogenicity prediction 155 
  Multiple sequence alignment 156 
Multiple sequence alignment of NNT protein sequences from different species was used to analyze 157 
structurally conserved regions and to predict putative effects of missense mutations. The sequences 158 
were found in the Uniprot database (http://www.uniprot.org/), aligned with ClustalW 159 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) using default parameters, displayed and then edited using 160 
Genedoc (http://www.psc.edu/index.php/user-resources/software/genedoc). 161 
  Software and databases 162 
For each new missense mutation, pathogenicity was predicted in silico using several programs: align 163 
GVGD, Polyphen 2, SIFT and Mutation taster. The Grantham score was calculated to predict the 164 
effect of substitutions between amino acids. This score looks at chemical properties to define a score 165 
range between 0 and 215. Higher scores indicate greater differences in the chemical properties 166 
between two amino acids (i.e., polarity and molecular volume) and may indicate a stronger (negative) 167 
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effect on protein structure and function. The dbSNP, EVS and ExAC browser databases were searched 168 
to determine if variants had already been reported. 169 
170 
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RESULTS 171 
 NNT gene sequencing 172 
Ten different NNT mutations, scattered throughout the gene, were found in thirteen families (eighteen 173 
patients) (Table 1, Figure 2). Seven of them were new mutations: two nonsense (p.Arg129*, 174 
p.Arg379*), two missense (p.Met337Val, p.Ala863Glu), two frameshift (p.Val665Profs*29, 175 
p.Ala704Serfs*19), and one start loss (c.3G>A (p.Met1?)). The p.Arg129* mutation was found in four 176 
families, all of Algerian origin (Table 2). Consanguinity was present in eight of the thirteen families 177 
and homozygous mutations were found in eleven families. No consanguinity was found in the other 178 
homozygous families (1, 5 and 10), but the parents in family 10 were from the same small village in 179 
France. The patients of families 4 and 12 were compound heterozygotes. Patient 12 was first thought 180 
homozygous for the mutation p.Arg71*. However, the mother did not carry the mutation and thus a 181 
deletion was suspected and thereafter confirmed by aCGH analysis and long range PCR sequenced 182 
step by step. For the three patients studied by MPS, all variants found in other genes were benign. 183 
 Pathogenicity prediction (Table 1) 184 
The p.Pro437Leu and p.Arg71* mutations have already been described9, 15. For the frameshift or 185 
nonsense mutations, the consequences should be premature truncated proteins or an absence of protein 186 
due to intervention of the nonsense-mediated decay system. The new mutation, c.3G>A (p.Met1?), 187 
affecting the translation initiation site, should switch this latter to an in-frame downstream methionine 188 
at codon 192. In the absence of its N-terminal part, the resulting NNT should be non-functional.  189 
To predict the pathogenicity of missense mutations, multiple alignments of NNT proteins were done in 190 
order to locate the changed residue in the protein structure and identify conservation between species 191 
18, 27
 (Figure 3).  192 
The p.Ala863Glu mutation is located in the transmembrane helix 14 (H14) of domain II and is highly 193 
conserved between species (Figure 3). H14 appears to indirectly facilitate proton translocation by 194 
influencing the centrally-located H9, H10, and H13, in which the proton channel is assumed to be 195 
located. In Escherichia coli, mutations of certain residues in these regions result in intermediate 196 
inhibitory effects 28. This mutation may disrupt the conformational changes responsible for 197 
interconversion of the open and occluded states 29. It may also play a role in coupling between the 198 
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redox state of the nucleotide and the proton movement in the protein, as it is near the NADP(H) 199 
binding domain. In in silico predictions, this mutation was most likely pathogenic using Align-GVGD 200 
class, probably damaging using Polyphen-2, deleterious using SIFT and disease causing using 201 
Mutation Taster. The high Grantham score of 107 is also concordant. This mutation is not reported in 202 
dbSNP, EVS or ExAC browser databases and has not been found in one hundred French Caucasian 203 
healthy controls. As expected, the parents of patient 7 were heterozygous as were his two healthy 204 
brothers. 205 
The missense mutation, p.Met337Val, was identified in the NAD(H) binding domain near the 206 
NAD(H) binding site. It should inhibit the hydride transfer from NADH to NADP+. The residue is 207 
highly conserved between species (Figure 3). The mutation was predicted to be deleterious by all of 208 
the mutation prediction tools mentioned above, despite a Grantham score of 21. This variation was not 209 
listed in the databases (dbSNP, EVS or ExAC browser) and not found in one hundred healthy controls 210 
from the Maghreb.  211 
 Clinical data at onset and follow-up (Table 2) 212 
Table 2 presents the clinical data and follow up for the eighteen patients reported. Only the 213 
predominant features are presented in the text.  214 
  Clinical presentation at age of diagnosis 215 
Severe hypoglycemia, sometimes leading to coma, was the main symptom at age of diagnosis in all 216 
but two patients (numbers 11a and 12). That symptom was often associated with infections and 217 
melanoderma. This latter, upon inquiry, was often reported to have been present before the 218 
hypoglycemia. Five out of the thirteen families had experienced multiple deaths of other children; 219 
although not diagnosed at the time, those deaths too were probably due to adrenal insufficiency and 220 
severe hypoglycemia. Patient 11a and 12 experienced salt wasting (SW) at onset without 221 
hypoglycemia and three other patients had a global adrenal insufficiency (patients 2b, 6, 8) with SW. 222 
The median age at onset in our cohort was 11.5 months (min-max: 1.5 months-4 years) (Table 2, 223 
Figure 4A). Most cases were diagnosed belatedly around the first year of life (8-18 months) but some 224 
involving stress conditions were diagnosed earlier. A difference in age at onset was detected between 225 
the subgroup with isolated glucocorticoid deficiency and that with global adrenal insufficiency. This 226 
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was the case for both our cohort alone (Kruskal-Wallis test: p-value =0.03379, Figure 4B) and our 227 
cohort aggregated with the data available in the literature (Kruskal-Wallis test: p-value =0.003705, 228 
Figure 4 C). However, no difference in age at onset was found between the subgroup homozygous for 229 
non-truncated mutations and that homozygous for truncated mutations (Kruskal-Wallis test: p-value 230 
=0.2172).  231 
  Follow-up 232 
At study end, the age of the 16 patients ranged from 4 to 57 years old, permitting a long patient 233 
follow-up. 234 
- Mineralocorticoid function:  235 
• Patient 3 had SW at age 15 then recurrence at 18, illustrating the importance of 236 
follow-up. Moreover, eight other patients (1, 2a, 4a-b, 10a-c, 13) had elevated renin 237 
and/or low aldosterone and needed mineralocorticoid or salt therapy. 238 
- Gonadotropic/genitalia function: 239 
• Patients 11a and 11b, both presented with cryptorchidism and underwent surgery for 240 
ectopic testes. 241 
• Two patients (7 and 9) had precocious puberty at age five, associated with testicular 242 
nodules, low or undetectable gonadotropins and high testosterone. Patient 9 had 243 
surgery revealing an interstitial Leydig cell adenoma. In this patient, a short GnRH 244 
analog therapy was discontinued and the adenoma removed. Thereafter, testosterone 245 
remained at pre-pubertal values.  246 
• For patient 12, testicular inclusions were detected at age 18 during imaging studies for 247 
azoospermia and were consistent with testicular adrenal rest tumor (TART). His 248 
azoospermia was associated with elevated FSH (LH: 9 mUI/ml, FSH: 18 mUI/ml) but 249 
normal testosterone (5.8 nmol/L). His karyotype was normal (46,XY) with no Y 250 
chromosome microdeletion. Increasing the dose of his glucocorticoid replacement 251 
therapy did not reduce the testicular inclusion and had no effect on spermatogenesis. 252 
•  Patient 1 had a testicular biopsy at age 31 for a left varicocele with epididymitis.  253 
- Heart function: 254 
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•  A transthoracic echocardiography in patient 1, at age 23 showed a typical and severe 255 
asymmetrical left ventricular hypertrophy (maximal wall thickness measured at the 256 
basilar septum: 36 mm). The resting left ventricular outflow gradient was measured at 257 
15 mmHg. There was no mitral regurgitation. The left atrium was dilated (25 mm²). 258 
Patient 9 at age six had normal heart function but with a left ventricular ejection 259 
fraction of 75%. 260 
- Other functions: 261 
• Two patients (2b and 9) had hypothyroidism with a thyroid gland in place. Patient 2b 262 
had congenital hypothyroidism and patient 9 hypothyroidism with low free T4 at age 263 
five and elevated TSH with no goiter at age seven.  264 
• Three patients had recurrent urinary tract infections (4b, 11a, 13). 265 
• We did not have information on social aspects for all the patients but four of them 266 
(patients 3, 5, 7 and 9) were experiencing poor academic performance or acquisition 267 
delays, possibly due to severe hypoglycemia.  268 
• None of the patients presented pancreatic dysfunction or impaired glucose tolerance. 269 
There were no growth disorders for patients who reached adult age. 270 
271 
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DISCUSSION 272 
Here, we report seven new NNT mutations identified in eighteen patients, eleven with FGD and seven 273 
with global adrenal insufficiency, who were members of thirteen families, i.e., 26% of the fifty 274 
families studied. 275 
The mutations were distributed throughout the gene and most led to a premature truncated protein or 276 
an absence of protein. The most frequent mutation found in our cohort was p.Arg129*, which was 277 
identified in four Algerian families, suggesting the possibility of a founder mutation similar to 278 
p.Gly200Ser in Palestine 12. We also identified two novel missense mutations, which should be 279 
pathogenic. Our patients with NNT mutations displayed a severe phenotype, with adrenal 280 
insufficiency often revealed by hypoglycemic convulsions. Most of the cases were diagnosed 281 
belatedly, around the first year of life (8-18 months). Some however were discovered earlier if stress 282 
conditions had occurred, i.e., intercurrent infections, suggesting the need of a stress to trigger the 283 
disease (Figure 4A). This is in accordance with the literature where the minimum age at diagnosis is 284 
three days 12 and the median age at onset is 12 months for the 29 patients for whom data are available 285 
9, 11-13, 15, 16
. Unlike those of Jazayeri et al, our data suggest earlier onset in patients with global adrenal 286 
deficiency compared to those with isolated glucocorticoid deficiency (Figure 4B and C). The 287 
phenotypic variability between patients having a same mutation or within a same family (family 2), 288 
suggests that there is no correlation between genotype and phenotype. 289 
It is clear that NNT mutations can result in global adrenal deficiency. In the literature and comparably 290 
to fourteen of our patients, five families were recently described with mineralocorticoid deficiency 291 
present at onset and three others with elevated renin or electrolytes imbalance 11-13, 16. Our patient 3 had 292 
salt wasting at age 15, although aldosterone requirements normally decrease throughout life 30. We 293 
observed phenotypic heterogeneity even within a same family. Patient 11a presented salt wasting 294 
whereas patient 11b had no mineralocorticoid deficiency. This emphasizes the need for careful 295 
monitoring of this function, since some patients classified as FGD may also have a slight 296 
mineralocorticoid defect. It has been shown that C57BL6/J mice carrying NNT mutations have 297 
disorganized zonae fasciculata with higher levels of apoptosis 9. As aldosterone requirement decreases 298 
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through life, the mineralocorticoid defect may be the consequence of extended damage to all adrenal 299 
zona. 300 
NNT has a role in the oxidative stress response and mutations in it may thus affect all tissues rich in 301 
mitochondria. For this reason too, patients with NNT mutations need to be closely monitored. Two in 302 
vitro studies on the fibroblasts 12 and lymphocyte mitochondria 31 of patients homozygous for missense 303 
NNT mutations showed an increase in ROS levels, a decrease of ATP content, and impaired 304 
morphology of mitochondria with reduced mitochondrial mass and increased mtDNA deletion due to a 305 
lack of thymidylate biosynthesis 12, 31. The results from those two studies suggest that all tissues can be 306 
injured, as do our results from the follow-up of patients with extra-adrenal defects.  307 
Although NNT is widely expressed in adrenal, heart, kidney, thyroid and adipose tissues, the most 308 
affected tissue in our cohort appeared to be the gonads 9. Two of our patients had cryptorchidism 309 
(patients 11a and b) and two others (7 and 9) presented similar histories involving, both at about five 310 
years of age, the development of palpable nodules on the testicular surface or testicular enlargement 311 
followed by the onset of puberty with high testosterone levels. These last two cases are comparable to 312 
that reported by Hershkovitz et al 13. For our patients 7 and 9, gonadotropins were in the normal pre-313 
pubertal range and the increase in testosterone seemed to be due to secretion by autonomous nodules 314 
responsible for the onset of puberty. Since the regression of puberty for patient 9 was due either to the 315 
removal of the adenoma or the short GnRH analog treatment, we cannot pronounce as to the central, 316 
peripheral or mixed origin of the precocious puberty. Reporting on a boy with a mutation in DAX-317 
1/NR0B1, Domenice et al concluded that chronic excessive ACTH levels may stimulate Leydig cells 318 
and lead to gonadotropin-independent precocious puberty 32, a view toward which Hershkovitz et al’s 319 
case 13 argues as well. In contrast, the testicular inclusions of our patient 12, associated with 320 
azoospermia but normal testosterone values at age 18, although not reduced by glucocorticoid therapy, 321 
should be TART, often found in congenital adrenal hyperplasia 33.  322 
To date, we have observed heart function impairment (progressive hypertrophic cardiomyopathy) in 323 
only one of our patients but cannot exclude future cases because of the mean age of our cohort and the 324 
subnormal imaging of patient 9. This underlines the specific role of NNT in heart tissue. In B6J-Sod2-325 
/- mice, the presence of a normal NNT allele preserves cardiac function, delays the onset of heart 326 
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failure, and extends survival to the end of gestation 24. In comparison, the suppression of NNT in 327 
zebrafish results in ventricular malformations and contractile dysfunctions 34. Moreover, in humans, 328 
relationships between decreased NNT activity, modified mitochondrial redox regulation and cardiac 329 
failure have been reported. In the failing human heart, a partial loss of NNT activity adversely affects 330 
NADPH-dependent enzymes and the capacity to maintain membrane potential. This contributes to a 331 
decline in bioenergetic capacity, redox regulation and antioxidant defense, exacerbating oxidative 332 
damage to cellular proteins 26. A recent report of a heterozygous frameshift mutation of NNT in 333 
humans with left ventricular noncompaction supports the assumption that NNT plays a major role in 334 
myocardium 34. However, Nickel et al demonstrated a completely opposing view. They reported that 335 
during heart pressure overload, NNT adopts a reverse mode contributing to oxidative stress from 336 
which mice with mutation in NNT are protected 35. Those puzzling new insights may suggest that the 337 
functional mode (forward or reverse) of NNT is dependent on the metabolic state. Nevertheless, 338 
TXNRD2 is in the same pathway of ROS detoxification and TXNRD2 heterozygous mutations in 339 
humans have also been linked to dilated cardiomyopathy. Thus, for now, cardiac follow-up should be 340 
done 10, 36. 341 
The thyroid gland, highly exposed to oxidative stress, was the third most-affected organ in our cohort. 342 
Beyond our two patients with hypothyroidism, probably due to some hormone synthesis defect, two 343 
other cases with subclinical hypothyroidism have been reported 16. The biosynthesis of thyroid 344 
hormones (TH) is an oxidative biochemical reaction that depends on the formation of peroxide. 345 
However, two studies have suggested that when thyroid cells are exposed to significant amount of 346 
ROS, thyroid peroxidase and iodide organification are inhibited 37, 38. Another argument is the 347 
prevalence of thyroid dysfunction in patients with Down syndrome who are under unusual increased 348 
oxidative stress 39. NNT mutations may disturb the balance between H2O2 produced for TH 349 
biosynthesis and anti-oxidants to protect cells from H2O2 mediated oxidative damages, thus leading to 350 
TH formation inhibition. Nevertheless, our patients with hypothyroidism were consanguineous and we 351 
cannot exclude that another gene involved in the thyroid may be mutated. 352 
Other functions in our patients were normal, especially growth and glucose metabolism. Glucose 353 
intolerance or diabetes in humans has not been reported in the setting of NNT mutation, although 354 
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defects in mitochondrial energy metabolism have also been implicated in diabetes. This contrasts with 355 
the impaired insulin secretion observed in NNT mutant mice for which only the β−cells seemed 356 
sensitive 40. Increased ROS usually plays a role in innate immunity against bacterial cyto-invasion 41. 357 
Despite that, three of our patients experienced recurrent urinary tract infections. We thus feel that 358 
additional studies are necessary to further investigate renal function.  359 
In conclusion, we report here mutations in the NNT gene, which was one of the most frequent 360 
molecular etiologies in our “atypical” congenital adrenal insufficiency cohort. Deducing from our 361 
results and those of other authors, mutations in NNT should be searched not only in FGD but also in 362 
global adrenal insufficiency. Above all, careful follow-up, especially for mineralocorticoid, puberty, 363 
fertility, heart and thyroid function, must be maintained for all patients. The MPS approach described 364 
in the methods section, with a large panel of genes including NNT, appears to be the most efficient for 365 
genetic diagnosis 16, 42. The analysis of more than one gene at a time is a powerful way to reach a 366 
diagnosis in diseases with phenotype heterogeneity. We note that more and more “atypical” cases of 367 
PAI are being described, for example STAR and CYP11A1 mutations in boys with PAI with or 368 
without DSD. 369 
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TABLE AND FIGURES LEGENDS 502 
Table 1: NNT mutations in thirteen families with PAI. d: domain, TMH: transmembrane helix, -: 503 
not applicable, NMD: nonsense-mediated decay 504 
 505 
Table 2: Clinical characteristics and follow-up of the patients with NNT mutations. -:  not determined, 506 
M: male, F: female, Nl: normal,*: deceased, yrs: age in years, ttt: treatment, MC: mineralocorticoid, 507 
GC: glucocorticoid, SW: salt wasting, ↘: decreased ↗: increased, LVEF: left ventricular fraction, 508 
ENT: ear, nose, throat. Major abnormalities are in bold. For two patients (4a and 9) the age of 509 
diagnosis was late despite an earlier onset.   510 
 511 
Figure 1: Role of NNT in free radical metabolism in the mitochondria ETC: electron transport chain 512 
GSSG: glutathione disulfide; GSH: glutathione; GPX: glutathione peroxidase; GR: glutathione 513 
reductase; TXNRD2: thioredoxin reductase; PRDX3: peroxiredoxin 3 514 
 515 
Figure 2: NNT Mutations. Comparison between the domain structure of NNT protein and NNT exons 516 
in humans. Above: nonsense or frameshift mutations; below: missense mutations. New mutations 517 
indicated by rectangles. Underlined mutation is probably a splicing mutation. 518 
. 519 
Figure 3: Partial multiple amino acid alignment of NNT in human, bovine, mouse, Caenorhabditis 520 
elegans, Escherichia coli and Acetabularia acetubulum. Alignment was performed in clustalW and 521 
edited with Genedoc. The mutant residues p.M337V and p.A863E and corresponding amino acids are 522 
shaded and show the conservation across all species. 523 
 524 
Figure 4: A. Age at presentation for the patients of our cohort GD: glucocorticoid deficiency, SW: salt 525 
wasting. B&C. Difference in age at presentation (Kruskal-Wallis test, *: significance at p<0.05) 526 
between the group of patients with glucocorticoid deficiency and the group with salt wasting +/- 527 
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glucocorticoid deficiency within our cohort (p-value =0.03379*) (B); our data aggregated with the 528 
data available in the literature (p-value =0.003705*)  (C).  529 
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Table 1 : NNT mutations in thirteen families with PAI 
d:domain, TMH: transmembrane helix, -: not applicable, NMD nonsense-mediated decay 
Nucleotide change 
(NM_012343.3) 
Exon 
Protein 
change 
(NP_036475) 
Protein consequence Domain 
Predictive software 
dbSNP  
 ID 
Allele count 
Family 
number 
Ref. 
GVGD SIFT Polyphen 2 
Mutation 
Taster 
ESP ExAC 
c.3G>A 2 p.M1? Start loss 
Pre-
sequence     
- 0/13006 0/121286 
 
9,14 
c.211 C>T 3 p.R71* 
Premature truncation 
at amino acid 71. 
NMD? 
dI 
    
- 0/13006 0/121286 1,4,12 15 
c.385 C>T 4 p.R129* 
Premature truncation 
at amino acid 129. 
NMD? 
dI 
    
- 0/13002 0/121286 2,3,4,11 
 
c.1009A>G 8 p.M337V 
Missense mutation at 
amino acid 337 in the -
DH binding domain 
protein 
dI 
less 
likely 
Deleterious 
Probably 
damaging 
Disease causing - 0/13006 0/121286 13 
 
c.1135C>T 9 p.R379* 
Premature truncation 
at amino acid 379. 
NMD? 
dI 
    
- 0/13006 0/121286 9 
 
c.1310C>T 10 p.P437L 
Missense mutation at 
amino acid 437 
Role in dI-dII/dIII 
communication 
dI 
less 
likely 
Deleterious 
Probably 
damaging 
Disease causing - 0/13006 1/120146 10 9 
c.1992_2005del 14 p.V665Pfs*29 
Frameshift: premature 
truncation at amino 
acid 694 
dII 
TMH7     
- 0/13006 0/121286 5 
 
c.2106_2109dup 15 p.A704Sfs*19 
Frameshift: premature 
truncation at amino 
acid 723 
dII  
TMH9     
- 0/13006 0/121286 6 
 
c.2588C>A 17 p.A863E 
Missense mutation  at 
amino acid 863 in the 
transmembrane 
domain (helix 14) 
dII 
TMH14 
Most 
Likely 
Deleterious 
Probably 
damaging 
Disease causing - 0/13006 0/121286 7 
 
c.(-51+1_-53-
1)_(381+1_382-
1)del 
2-3 p.0? 
Start loss. Absence of 
protein        
0/121286 12  
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Table 2: Clinical characteristics and follow-up of the patients with NNT mutations. 
-:  not determined, M: male, F: female, Nl: normal,*: deceased, yrs: years, ttt: treatment, MC: mineralocorticoid, GC: glucocorticoid, SW: salt wasting, ↘: decreased ↗: increased, 
LVEF: left ventricular fraction, ENT: ear, nose, throat. Major abnormalities are in bold. For two patients (4a and 9) the age of diagnosis was late despite an earlier onset. 
Family Origin 
Consan- 
guinity 
NNT mutation 
NP_036475 
Sex 
Age 
(yrs) 
Age at 
 diagnosis 
 (months or yrs 
where indicated) 
Clinical data at age of diagnosis Mineralocorticoid defect Gonads Heart Thyroid Related death 
1 French no 
p.R71*/  
p.R71* 
M 43 14 hypoglycemia, melanoderma 
thirst for salt, MC ttt 
(↗renin) 
onset of puberty at 12 yrs, 
 Nl testicular function, 
surgery for varicocoele 
hypertrophic 
myocardiopathy 
Nl 
brother 
 at 2 yrs 
2a 
Algerian yes 
p.R129*/  
p.R129* 
M 32 6 
hypoglycemic convulsions, 
delay of diagnosis due to GC therapy for 
asthma  
MC ttt at 3 yrs  
(↗ renin) 
onset of puberty 
at 13 yrs 9 months 
 - Nl   
2b  M 15 3 
hypoglycemic convulsions, 
SW 
MC ttt, 
 SW at 12 yrs after an 
attempt to stop MC ttt 
onset of puberty at 12 yrs, 
low testosterone at 15 yrs  
Nl imaging 
 (12 yrs) 
congenital hypothyroidism 
with thyroid gland in place 
sister  
at 7 months 
3 Algerian yes 
p.R129*/  
p.R129* 
F 19 15 hypoglycemia, asthenia, melanoderma 
no MC ttt but 4 adrenal 
crises with ↗ renin 
↘aldosterone  
(4, 7, 8 and 10 yrs) 
SW at 15 and 18 yrs 
menarche (11 yrs), 
 Nl menstrual cycle 
Nl imaging  
(15 yrs) 
Nl no 
4a French/ 
Algerian 
no 
p.R71*/  
p.R129* 
F 30 
1.5 (onset) 
/12 
hypoglycemic convulsions following 
gastroenteritis 
MC ttt at 2 yrs  
(↗ renin) 
menarche (11 yrs),  
two children 
 -  - no 
4b F 23 10 
hypoglycemic convulsions following 
gastroenteritis 
no MC ttt but ↗ renin -  -  - no 
5 French no 
p.V665Pfs*29/ 
p.V665Pfs*29  
M 14 19 
hypoglycemic convulsions on ENT 
infections 
no 
onset of puberty at 12 yrs 
low testosterone at 13 yrs  
Nl imaging  
(11 yrs) 
Nl no 
6 Turkish yes 
p.A704Sfs*19/  
p.A704Sfs*19 
F 18 8 
hypoglycemia, asthenia, melanoderma,  
weight loss, fever, SW 
MC ttt menarche (12.5 yrs)  - 
transient subclinical 
hypothyroidism 
 (TSH: 6.8 mUI/L at 5yrs) 
no 
7 Moroccan yes 
p.A863E/  
p.A863E 
M 5 13 hypoglycemic convulsions no 
precocious puberty 
 with 3 nodular testis 
Nl imaging  
(4 yrs) 
Nl no 
8 Mauritian yes p.M1?/p.M1? F 8 9 hypoglycemic coma, SW MC ttt no pubertal symptoms  - Nl  no 
9 Algerian yes 
p.R379*/ 
p.R379* 
M 10 
22 (onset) 
/8yrs 
Misdiagnosed at 22 months  
(several hyperthermic convulsions, 
psychomotor retardation, sodium 
valproate ttt),  
all symptoms improved after 
glucocorticoid therapy initiated at 8 yrs  
no 
Leydig cell adenoma (5 yrs) 
following by precocious 
puberty 
subNl imaging 
at 6 yrs 
 (LVEF at 75%) 
subclinical hypothyroidism 
 (TSH: 3.5 mUI/L at 5 yrs and 
10.5 at 7 yrs), thyroid 
hormone treatment 
no 
10a 
French no 
p.P437L/ 
p.P437L 
M 57 4 yrs melanoderma, asthenia salt craving, MC ttt Nl puberty  -  - no 
10b M 51 18 melanoderma, asthenia salt craving, MC ttt Nl testicular function at 49 yrs 
Nl imaging 
 (51 yrs) 
Nl no 
10c F  4* 16 familial story, deceased at 4 yrs MC ttt  -  -  - no 
11a 
Algerian yes 
p.R129*/  
p.R129* 
M 6 2 SW 
SW (2 months, 4 yrs), 
 MC ttt 
cryptorchidism (surgery) 
Nl imaging  
(2 yrs) 
 - 
Brother 
 at 8 months 
11b M 8 4 yrs hypoglycemia (Nl at 3 yrs) no cryptorchidism (surgery) 
Nl imaging 
 (2 yrs) 
 - 
 Brother 
 at 8 months 
12 French no 
p.R71*/  
del ex2-3 
M 35 10 SW SW, MC ttt bilateral TART, azoospermia  - Nl no 
13 Algerian yes 
p.M337V/ 
p.M337V 
F 9 8 melanoderma, asthenia 
i↗ renin,↘ aldosterone  
(16 months, 12 yrs),  
salt , no MC ttt 
no pubertal symptoms  - Nl 
Sister 
at 4 yrs 
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p.M1? 
p.Y201Kfs*1 
p.H370* 
p.Q383* 
p.Q452Rfs*42 p.T689Lfs*32 
p.S193N 
p.H365P p.P437L 
p.A533V 
p.G664R 
p.G678R 
p.G862D p.A1008P 
p.N1009K 
p.S22Pfs*6 
p.R71* 
p.R129* p.V665Pfs*2 
p.A704Sfs*19 
p.A863E 
100 amino acids 
Pre 
sequence Domain I, NAD(H) binding Domain II, membrane spanning 
Domain III,  
NADP(H) binding 
2 9 9 6 7 10 11 12 13 17 19 19 20 21 22 3 4 14 15 17 18 16 8 5 
NAD(H) site NADP(H) site 
p.L977P 
p.I622Dfs*1 p.Q557X 
p.F215S 
p.R379* 
p.M337V 
p.T357A 
p.G200S 
p.Asp999Glyfs*2 
p.Y388S 
p.H421Sfs*4 p.W43Vfs*2 
p.0? (del ex2-3) 
p.D178G p.H370R 
p.D590Efs*29 p.P799Qfs*22 
p.M880* 
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Human 
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Figure 4: A. Age at presentation for the patients of our cohort GD: glucocorticoid deficiency, SW: salt 
wasting. B&C. Difference in age at presentation (Kruskal-Wallis test, *: significance at p<0.05) between the 
group of patients with glucocorticoid deficiency and the group with salt wasting +/- glucocorticoid deficiency 
within our cohort (p-value =0.03379*) (B); our data aggregated with the data available in the literature (p-
value =0.003705*)  (C).  
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